Radius Health (RDUS) Coverage Initiated by Analysts at Morgan Stanley

Investment analysts at Morgan Stanley started coverage on shares of Radius Health (NASDAQ:RDUS) in a report released on Monday, Marketbeat Ratings reports. The firm set an “overweight” rating and a $57.00 price target on the biopharmaceutical company’s stock. Morgan Stanley’s target price would suggest a potential upside of 43.22% from the company’s previous close.

Several other research firms also recently weighed in on RDUS. Zacks Investment Research downgraded Radius Health from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 target price on shares of Radius Health in a research report on Friday, October 6th. Citigroup reissued a “hold” rating and set a $43.00 target price on shares of Radius Health in a research report on Monday, January 22nd. BidaskClub raised Radius Health from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $58.00 target price on shares of Radius Health in a research report on Thursday, January 18th. One analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. Radius Health has a consensus rating of “Hold” and an average price target of $50.75.

Radius Health (RDUS) traded up $1.06 during midday trading on Monday, hitting $39.80. The stock had a trading volume of 625,313 shares, compared to its average volume of 965,963. The company has a market cap of $1,727.49, a P/E ratio of -7.52 and a beta of 1.10. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health has a 52-week low of $24.66 and a 52-week high of $49.16.

Radius Health (NASDAQ:RDUS) last released its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million during the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter in the prior year, the company posted ($1.07) earnings per share. research analysts expect that Radius Health will post -5.62 EPS for the current fiscal year.

In other Radius Health news, VP Brent Hatzis-Schoch acquired 1,778 shares of the company’s stock in a transaction that occurred on Friday, November 10th. The stock was bought at an average price of $28.09 per share, for a total transaction of $49,944.02. Following the acquisition, the vice president now directly owns 2,278 shares in the company, valued at $63,989.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the acquisition, the insider now owns 5,698,799 shares in the company, valued at $149,593,473.75. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 108,578 shares of company stock valued at $3,017,416. 15.00% of the stock is owned by company insiders.

Several hedge funds have recently modified their holdings of RDUS. Cubist Systematic Strategies LLC purchased a new stake in shares of Radius Health in the 3rd quarter worth $110,000. Ameritas Investment Partners Inc. raised its position in shares of Radius Health by 19.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,266 shares of the biopharmaceutical company’s stock worth $148,000 after acquiring an additional 541 shares in the last quarter. Advisor Group Inc. raised its position in shares of Radius Health by 267.2% in the 2nd quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares in the last quarter. Amalgamated Bank bought a new position in shares of Radius Health in the 2nd quarter worth $211,000. Finally, Principal Financial Group Inc. raised its position in shares of Radius Health by 14.1% in the 2nd quarter. Principal Financial Group Inc. now owns 6,809 shares of the biopharmaceutical company’s stock worth $308,000 after acquiring an additional 839 shares in the last quarter.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2018/01/29/radius-health-rdus-coverage-initiated-by-analysts-at-morgan-stanley.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply